4
Changes in Ownership
Rapport Therapeutics, Inc. Filed Acc 0001193125-26-368244
Chief Development Officer sold 50,160 shares at an average $50.47 ($2,531,582)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Yeleswaram Krishnaswamy Chief Development Officer | 2026-08-24 | Sale 10b5-1 | −13,160 | $50.00 | $657,978 | 232,862 | D |
| Yeleswaram Krishnaswamy Chief Development Officer | 2026-08-25 | Sale 10b5-1 | −20,799 | $50.31 | $1,046,421 | 212,063 | D |
| Yeleswaram Krishnaswamy Chief Development Officer | 2026-08-25 | Sale 10b5-1 | −16,201 | $51.06 | $827,184 | 195,862 | D |
| Open-market sales · 50,160 sh · avg $50.47 · $2,531,582 | |||||||
Loading xslF345X06/ownership.xml…